Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

S. Aureus Bloodstream Infection

Study type

Observational

Funder types

Industry

Identifiers

NCT01212601
NIS-ICN-DUM-2010/1

Details and patient eligibility

About

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Full description

MC MD

Enrollment

203 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient has received CUBICIN treatment, decided by treating physician
  • A patient who is considered as ethnic Chinese
  • Provision of subject informed consent

Exclusion criteria

A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

Trial design

203 participants in 1 patient group

1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

Ā© Copyright 2024 Veeva Systems